Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- REGULATORY NEWS IN BRIEF
May 19, 2003
- Korosho's Project Team Calls For Measures Regarding Insulin Preparations
May 12, 2003
- Mie Prefecture to Establish Clinical Trial Network
May 12, 2003
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
May 12, 2003
- BULLETIN
May 12, 2003
- Yamanouchi's 1st Genomic Drug to Enter Clinical Stage in 2005
May 12, 2003
- Disagreement on Merger Ratio Ends Merger Plan of Teijin, Kyorin
May 12, 2003
- Two Business Plans Selected in 3rd Bio-business Competition
May 12, 2003
- PAL Amendments as Related to GMP Explained by Korosho Official
May 12, 2003
- Legal Basis for Regenerative Medicine Regulations Proposed by JHSF
May 12, 2003
- Allergan Launches Kyorin's Gatifloxacin Ophthalmic Solution in US
May 12, 2003
- PRESS SEMINAR
May 12, 2003
- Fujisawa: Sales Increase for 4 Consecutive Years
May 12, 2003
- RESEARCH & DEVELOPMENT NEWS IN BRIEF
May 12, 2003
- NEW PRODUCTS
May 12, 2003
- OTC NEWS IN BRIEF
May 12, 2003
- IMCJ Designated for Treatment of Specific Infectious Diseases
May 12, 2003
- MEDICAL DEVICE NEWS IN BRIEF
May 12, 2003
- Ribavirin Not Recommended for SARS at Present: Korosho Expert WG
May 12, 2003
- DIAGNOSTIC NEWS IN BRIEF
May 12, 2003
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…